PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Top Cited Papers
Open Access
- 13 February 2019
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today: Technologies
- Vol. 31, 15-27
- https://doi.org/10.1016/j.ddtec.2019.01.002
Abstract
No abstract availableKeywords
Funding Information
- Swedish Research Council (2016-00294)
- NIH (R35CA197589)
This publication has 105 references indexed in Scilit:
- Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACsProceedings of the National Academy of Sciences of the United States of America, 2013
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia, 2012
- Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α InteractionJournal of the American Chemical Society, 2012
- Protein Knockdown Using Methyl Bestatin−Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding ProteinsJournal of the American Chemical Society, 2010
- The 26 S Proteasome: From Basic Mechanisms to Drug TargetingPublished by Elsevier BV ,2009
- Predicting druggable binding sites at the protein–protein interfaceDrug Discovery Today, 2008
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomicsBioorganic & Medicinal Chemistry Letters, 2008
- Targeted Degradation of the Aryl Hydrocarbon Receptor by the PROTAC Approach: A Useful Chemical Genetic ToolChemBioChem, 2007
- What Is the Right Dose? The Elusive Optimal Biologic Dose in Phase I Clinical TrialsJournal of Clinical Oncology, 2006
- Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted DegradationJournal of the American Chemical Society, 2004